May 9, 2005Archives of Internal Medicine
Risk of Hospitalization for Myocardial Infarction Among Users of Rofecoxib, Celecoxib, and Other NSAIDs
Key result
Current use of rofecoxib was associated with an increased risk of hospitalization for myocardial infarction compared with nonuse of nonaspirin NSAIDs (adjusted RR 1.80; 95% CI 1.47-2.21).
Why the study?
Does the use of nonaspirin NSAIDs increase the risk of hospitalization for myocardial infarction in the general population?
Population
10,280 cases of first-time hospitalization for myocardial infarction and 102,797 sex- and age-matched non-MI…
Comparison
Current use of nonaspirin NSAIDs including… vs Nonusers of any category of nonaspirin NSAIDs.
Design
Case-control
Authors
Discussion
Loading...
Member takes
Implication
May support avoiding rofecoxib in at-risk patients; leaves open class effects of other nonaspirin NSAIDs.
Study Design
Type
Case-Control (n=113,077)
Multicenter
Yes
Structured PICO
Does the use of nonaspirin NSAIDs increase the risk of hospitalization for myocardial infarction in the general population?
P
Population
113,077 individuals, comprising 10,280 cases of first-time hospitalization for MI and 102,797 matched controls, evaluated for NSAID exposure.
E
Exposure
Current use of nonaspirin NSAIDs including rofecoxib, celecoxib, other cyclooxygenase-2 selective inhibitors, naproxen, and other conventional nonaspirin NSAIDs.
C
Comparator
Nonusers of any category of nonaspirin NSAIDs.
O
Outcome
First-time hospitalization for myocardial infarction.hard clinical
Main Result
Relative Risk: 1.8 (95% CI 1.47–2.21)
Current and new use of all classes of nonaspirin NSAIDs, including COX-2 inhibitors and conventional NSAIDs, is associated with an increased risk of hospitalization for myocardial infarction.
Limitations
- Increased risk estimates may partly reflect unmeasured bias
Cite This Study
Søren Paaske Johnsen (2005) conducted a case-control in Myocardial infarction (n=113,077). Rofecoxib vs. Nonusers of any category of nonaspirin NSAIDs was evaluated on Hospitalization for myocardial infarction (RR 1.80, 95% CI 1.47-2.21). Current use of rofecoxib was associated with an increased risk of hospitalization for myocardial infarction compared with nonuse of nonaspirin NSAIDs (adjusted RR 1.80; 95% CI 1.47-2.21).